Satsuma Pharmaceuticals Announces the Appointment of Thomas M. Soloway to its Board of Directors
Retrieved on:
Tuesday, July 7, 2020
We are excited to welcome Tom to our Board of Directors, stated Heath Lukatch, Ph.D., Chairman of Satsumas Board of Directors.
Key Points:
- We are excited to welcome Tom to our Board of Directors, stated Heath Lukatch, Ph.D., Chairman of Satsumas Board of Directors.
- "I am very pleased to join the Satsuma board of directors during this transformational time for the company," commented Mr. Soloway.
- I look forward to working closely with the Satsuma board and management team to deliver on an exciting future for the company."
- Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical Company developing a novel therapeutic product for the acute treatment of migraine, STS101.